Thelansis

  Gallbladder cancer (GC) is a rare malignancy but represents almost half of all biliary tract cancer. The chronic inflammation of the bile duct tissue accumulates successive genomic mutations that lead to malignant transformation. The most common mutations described are oncogenes K-RAS and tumor suppressors beta-catenin (CTNNB1). The majority of histopathology changes in gallbladder cancer appear as adenocarcinomas (90%). Gallbladder cancer patients are frequently asymptomatic at presentation or describe vague symptoms such as abdominal pain, anorexia, indigestion, weakness, nausea or vomiting, loss of appetite, and weight loss, and can present with jaundice, which can easily be misdiagnosed as cholecystitis. Biliary obstruction by cancer causes jaundice, clay-colored stools, cola-colored urine, and skin pruritus. The incidence of Gallbladder cancer (GC) ranges from 3 to 4 per 100,000 in the USA.   Thelansis’s “Gallbladder Cancer (GC) Market Outlook, Epidemiology...

 Gallbladder cancer (GC) is a rare malignancy but represents almost half of all biliary tract cancer. The chronic inflammation of the bile duct tissue accumulates successive genomic mutations that lead to malignant transformation. The most common mutations described are oncogenes K-RAS and tumor suppressors beta-catenin (CTNNB1). The majority of histopathology changes in gallbladder cancer appear as adenocarcinomas (90%). Gallbladder cancer patients are frequently asymptomatic at presentation or describe vague symptoms such as abdominal pain, anorexia, indigestion, weakness, nausea or vomiting, loss of appetite, and weight loss, and can present with jaundice, which can easily be misdiagnosed as cholecystitis. Biliary obstruction by cancer causes jaundice, clay-coloured stools, cola-colored urine, and skin pruritus. ·        The incidence of Gallbladder cancer (GC) ranges from 3 to 4 per 100,000 in the USA. Thelansis’s “Gallbladder Cancer (GC) Marke...